TrialAntimicrobial agents and chemotherapy2014

Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.

Kelly E Dooley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.